Terri S Armstrong1, Elizabeth Vera-Bolanos1, Alvina Acquaye1, Mark R Gilbert1, Tito R Mendoza1. 1. Department of Family Health , University of Texas Health Science Center School of Nursing, Houston, Texas (T.S.); Department of Neuro-Oncology , The University of Texas: MD Anderson Cancer Center , Houston, Texas (T.S., E.V., A.A., M.R.G.); Department of Symptom Research , The University of Texas: MD Anderson Cancer Center , Houston, Texas (T.R.M.).
Abstract
BACKGROUND: Understanding the severity of symptoms is an integral part of patient care. The MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) was developed using a 24-hour recall period. The choice of recall period is dependent on the treatment and disease of interest. The aim of this study was to evaluate the congruence and equivalency of 24-hour and 7-day symptom reporting using the MDASI-BT. METHOD: Adult brain tumor patients completed the MDASI-BT using 24-hour and 7-day recall periods and a tablet format. Equivalence and congruence were determined using equivalency testing and Bland-Altman analysis. Reliability and known group's validity were then assessed by use of Cronbach's alpha and evaluating differences based on performance status. RESULTS: One hundred patients (mean age, 48 y; range 19 y-77 y), who were primarily white (86%) males (62%) with a variety of brain tumors, most commonly glioblastoma (69%), participated. KPS scores ranged from 50%-100%, with 28% of participants scoring 80% or lower. Overall severity reporting using the 7-day recall was congruent and equivalent with the 24-hour rating, with difference scores of one point or less on the overall instrument and individual symptoms. The 7-day recall period instrument demonstrated psychometric properties similar to the established 24-hour recall instrument. CONCLUSION: This study supports the use of the 7-day recall period in addition to the 24-hour recall period for symptom reports of patients with primary brain tumors. Future studies should continue to explore the reliability and validity of this recall period and its utility in other central nervous system tumor populations.
BACKGROUND: Understanding the severity of symptoms is an integral part of patient care. The MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) was developed using a 24-hour recall period. The choice of recall period is dependent on the treatment and disease of interest. The aim of this study was to evaluate the congruence and equivalency of 24-hour and 7-day symptom reporting using the MDASI-BT. METHOD: Adult brain tumorpatients completed the MDASI-BT using 24-hour and 7-day recall periods and a tablet format. Equivalence and congruence were determined using equivalency testing and Bland-Altman analysis. Reliability and known group's validity were then assessed by use of Cronbach's alpha and evaluating differences based on performance status. RESULTS: One hundred patients (mean age, 48 y; range 19 y-77 y), who were primarily white (86%) males (62%) with a variety of brain tumors, most commonly glioblastoma (69%), participated. KPS scores ranged from 50%-100%, with 28% of participants scoring 80% or lower. Overall severity reporting using the 7-day recall was congruent and equivalent with the 24-hour rating, with difference scores of one point or less on the overall instrument and individual symptoms. The 7-day recall period instrument demonstrated psychometric properties similar to the established 24-hour recall instrument. CONCLUSION: This study supports the use of the 7-day recall period in addition to the 24-hour recall period for symptom reports of patients with primary brain tumors. Future studies should continue to explore the reliability and validity of this recall period and its utility in other central nervous system tumor populations.
Authors: Qiuling Shi; Peter C Trask; Xin Shelley Wang; Tito R Mendoza; Winifred A Apraku; Maggie Malekifar; Charles S Cleeland Journal: J Pain Symptom Manage Date: 2010-06-25 Impact factor: 3.612
Authors: Terri S Armstrong; Elizabeth Vera-Bolanos; Ibrahima Gning; Alvina Acquaye; Mark R Gilbert; Charles Cleeland; Tito Mendoza Journal: Cancer Date: 2011-01-24 Impact factor: 6.860
Authors: T S Armstrong; T Mendoza; I Gning; I Gring; C Coco; M Z Cohen; L Eriksen; Ming-Ann Hsu; M R Gilbert; C Cleeland Journal: J Neurooncol Date: 2006-04-06 Impact factor: 4.130
Authors: Terri S Armstrong; Ibrahima Gning; Tito R Mendoza; Jeffrey S Weinberg; Mark R Gilbert; Melissa L Tortorice; Charles S Cleeland Journal: J Pain Symptom Manage Date: 2008-08-03 Impact factor: 3.612
Authors: Terri S Armstrong; Jeffrey S Wefel; Meihua Wang; Mark R Gilbert; Minhee Won; Andrew Bottomley; Tito R Mendoza; Corneel Coens; Maria Werner-Wasik; David G Brachman; Ali K Choucair; Minesh Mehta Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544
Authors: Jaishri O Blakeley; Stephen Joel Coons; John R Corboy; Nancy Kline Leidy; Tito R Mendoza; Jeffrey S Wefel Journal: Neuro Oncol Date: 2016-03 Impact factor: 12.300
Authors: Marijke B Coomans; Marthe C M Peeters; Johan A F Koekkoek; Jan W Schoones; Jaap Reijneveld; Martin J B Taphoorn; Linda Dirven Journal: Cancers (Basel) Date: 2020-11-24 Impact factor: 6.639
Authors: Puja Aggarwal; Katherine A Hutcheson; Adam S Garden; Frank E Mott; Charles Lu; Ryan P Goepfert; Clifton D Fuller; Stephen Y Lai; G Brandon Gunn; Mark S Chambers; Erich M Sturgis; Ehab Y Hanna; Sanjay Shete Journal: Cancer Date: 2021-08-06 Impact factor: 6.860